Komori
Other Disclosures4894Cuorips Inc.Pharmaceuticals

Notice Regarding Insurance Coverage for ReHeart

The Company's product, リハート®, became eligible for public health insurance coverage on 1 September 2026, and a reimbursement price was set.

Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
53200000
Yen (reimbursement price)
Wording
Definitive
How definitive the wording is.

Announced details

リハート®
Applicable field (uses covered by this announcement)

Treatment of severe heart failure caused by ischemic cardiomyopathy in cases where standard treatments, including drug therapy and invasive treatment, have been insufficiently effective

Launch date1 September 2026 (date listed for reimbursement; actual)
Relationship between the counterparty and the company
Cuorips Inc.4894
Relationship with the Company

Public health insurance coverage was approved for a product the Company has been developing.

CounterpartyMinistry of Health, Labour and Welfare (public health insurance coverage through the Official Gazette and notifications of the Ministry of Health, Labour and Welfare)
Offering price

¥53,200,000 (reimbursement price)

Impact on Business Performance

The impact is already reflected in the full-year consolidated earnings forecasts announced on 28 July 2026. If any revision becomes necessary, the Company will make a timely disclosure.

The company does not address Contract Value.

Source (materials cited by the company)

Official Gazette (notification of the Ministry of Health, Labour and Welfare)

Announced details
ItemDetails
Names of Products / Services Coveredリハート®
CounterpartyMinistry of Health, Labour and Welfare (public health insurance coverage through the Official Gazette and notifications of the Ministry of Health, Labour and Welfare)
Relationship with the CompanyPublic health insurance coverage was approved for a product the Company has been developing.
Offering price¥53,200,000 (reimbursement price)
Launch date1 September 2026 (date listed for reimbursement; actual)
Applicable areaTreatment of severe heart failure caused by ischemic cardiomyopathy in cases where standard treatments, including drug therapy and invasive treatment, have been insufficiently effective
Impact on Business PerformanceThe impact is already reflected in the full-year consolidated earnings forecasts announced on 28 July 2026. If any revision becomes necessary, the Company will make a timely disclosure.
SourceOfficial Gazette (notification of the Ministry of Health, Labour and Welfare)
Items this document does not state (10)
Counterparty overviewContract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Coverage under public health insurance (listed for reimbursement) for リハート® was announced through the Official Gazette (notification of the Ministry of Health, Labour and Welfare).

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Insurance Coverage for ReHeart | Cuorips Inc. (4894) timely disclosure | Komori